Clinical trials: Patients with Advanced Solid Tumors
Acute Leukemia, Advanced Solid Tumor
Evaluation of Bibliotherapy by Students and Patients With Cancer
Research has demonstrated the positive effects of bibliotherapy (the use of reading in the treatment of patients), such as increased self-awareness, increased empathy, hope and decreased negativity.
- Trial name
- NCT03969082
- Testing
- Bibliotherapy
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Neoplasm Metastasis
Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours
Open, non-randomized, radiolabelled, single centre study designed to characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced…
- Trial name
- NCT00633269
- Testing
- AZD2281
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Advanced Malignant Solid Tumors
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan.
- Trial name
- NCT00728468
- Testing
- PF-00299804
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Solid Tumor
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in…
- Trial name
- NCT04931823
- Testing
- CPO-100
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Advanced Solid Tumor, Adult
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose…
- Trial name
- ATTACC (NCT04972110)
- Testing
- RP-3500 (camonsertib)
- Where
- 13 sites in United States
- Volunteers
- 156 people
- Sponsor
- Repare Therapeutics
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04771520
- Testing
- Avapritinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Cancer, HER2 Gene Mutation
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Prospective, Basket, Open-label, Multi-dose, Single-arm, Simon's two-stage, Multi-center trial Study drug : neratinib + herzuma (trastuzumab biosimilar)
- Trial name
- NCT06083662
- Testing
- Neratinib Maleate
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Korea University Guro Hospital
Cancer, Neoplasms
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
IT141 is a novel nanoparticle formulation of SN-38, the active metabolite of irinotecan, and is intended to deliver more drug to the tumor with reduced toxicity on normal tissues.
- Conditions
- Cancer, Neoplasms, Tumors, Refractory Solid Tumors
- Trial name
- NCT03096340
- Testing
- IT-141
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Intezyne Technologies, Inc.
Neoplasms, Neoplasm Malignant
AIMS Cancer Outcomes Study
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in…
- Conditions
- Neoplasms, Neoplasm Malignant, Advanced Cancer, Advanced Solid Tumor
- Trial name
- ACOS (NCT04495790)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Advanced Integrative Medical Science Institute
Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006018
- Testing
- BMS-214662, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Solid Tumors, Lymphoma, Non-Hodgkin
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Part 1 and Part 2 of this trial will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of SCH 727965 administered every 3 weeks as a 2 hour intravenous (IV) infusion (Part 1), and as an…
- Conditions
- Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT00871910
- Testing
- SCH 727965, Aprepitant, Ondansetron
- Volunteers
- 81 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid…
- Trial name
- NCT06290388
- Testing
- 23ME-01473
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- 23andMe, Inc.
Solid Tumor, Metastatic Cancer
Study of GNX102 in Patients With Advanced Solid Tumors
GNX102 is a humanized monoclonal antibody (mAb), an engineered biotechnology product, developed by GlycoNex that targets certain cancer cells by binding with high affinity to specific structures on cancer cells.
- Conditions
- Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm
- Trial name
- NCT04250597
- Testing
- GNX102
- Where
- 8 sites in United States, Taiwan
- Volunteers
- 46 people
- Sponsor
- GlycoNex, Inc.
Lymphoma, Solid Neoplasm
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of ribociclib and gemcitabine hydrochloride in treating patients with solid tumors or lymphoma that have spread to other places in the body and usually cannot be cured or…
- Trial name
- NCT02414724
- Testing
- Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Cancer, Solid Tumor Cancer
Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor
- Conditions
- Cancer, Solid Tumor Cancer, Biomarkers
- Trial name
- NCT06944457
- Testing
- MPD-1
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Pharosgen Co.,Ltd
Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that…
- Conditions
- Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma
- Trial name
- NCT02535312
- Testing
- Cisplatin, Methoxyamine, Pemetrexed Disodium
- Where
- 14 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma.
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04387071
- Testing
- Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
- Trial name
- NCT00421044
- Testing
- Patupilone/EPO906
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
The main aim of this study is to assess how the human body of adults with advanced or metastatic solid tumors absorbs, distributes, metabolizes and excretes subasumstat following a single 1 hour infusion of subasumstat.
- Trial name
- NCT05976334
- Testing
- [14C] Subasumstat, Subasumstat
- Where
- 2 sites in Hungary
- Volunteers
- 3 people
- Sponsor
- Takeda
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT05694364
- Testing
- Fludarabine, Cyclophosphamide, PRGN-3007
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.